Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104259 · ClinicalTrials.gov registry record · Phase 1
Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01104259 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 50 participants.
The verdict
NCT01104259, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of veliparib when given together with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has returned or spread to other parts of the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with combination chemotherapy may be a better treatment for breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- OTHER pharmacological study
- DRUG vinorelbine tartrate
- DRUG veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-07 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104259
The ClinicalTrials.gov registry entry for NCT01104259 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01104259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104259 about?
NCT01104259 is a clinical study titled "Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer". This phase I trial studies the side effects and best dose of veliparib when given together with cisplatin and vinorelbine ditartrate in treating patients with breast cancer that has returned or spread to other parts of the body. Veliparib may stop the growth of tumor cells by blocking some of the en...
What is the current status of trial NCT01104259?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-07. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01104259?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), pharmacological study (OTHER), vinorelbine tartrate (DRUG), veliparib (DRUG).
Who is sponsoring clinical trial NCT01104259?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.